A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Summary

This study is designed for multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injection of IBI333 in subjects with neovascular age-related macular degeneration (nAMD).

Timeline

Start

2023-02-27

Primary completion

2023-12-07

Completion

2024-04-23

Drugs

Indications